Z6·尊龙凯时「中国」官方网站z6尊龙

Chengdu, China - MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") recently attended the 13th Chinese Vascular Surgery Congress of the Vascular Surgery Branch of Chinese Medical Association in Chengdu of Sichuan Province from August 11 to August 14, and displayed several innovative endovascular products. Around 1,000 domestic experts gathered together in the congress to dive deep into the application progress and prospect of drug, material, equipment and technique related with vascular surgery, with key note speeches on hot topics in the field of vascular surgery.

During the meeting, MicroPort® Endovascular displayed several innovative products such as Minos™ Ultra Low Profile Abdominal Aortic Aneurysm ("AAA") Stent-Graft and Hercules™-T Low Profile AAA Stent-Graft and Delivery System with special areas for trying simulators and watching video. Many attendees were attracted to visit the booth, try out simulators and inquire product information with great interest.

Meanwhile, MicroPort® Endovascular launched the first issue of "Endovascular View  Special Issue for the 13th Chinese Vascular Surgery Congress," in which Professor Jichun Zhao of West China Hospital of Sichuan University, Professor Jianhua Huang of Xiangya Hospital of Central South University, Professor Weiliang Jiang of the Second Affiliated Hospital of Harbin Medical University, Professor Xiao Qin of the First Affiliated Hospital of Guangxi Medical University, Professor Canhua Luo of the Foshan First People’s Hospital, and Professor Hong Zhang of the Affiliated Hospital of Chengde Medical University were invited to talk about the clinical applications of Minos™ Ultra Low Profile AAA Stent-Graft and Hercules™-T Low Profile AAA Stent-Graft and Delivery System in TEVAR and EVAR, and share their vision for technology and product R&D in the endovascular treatment of aortic diseases. Minos™ Ultra Low Profile AAA Stent-Graft and Hercules™-T Low Profile AAA Stent-Graft have lower profile delivery system compared to other aortic stents-graft in the China market. Such feature lowers the requirement for the diameter of introducing femoral artery in the AAA endovascular surgery, which is expected to benefit many female and Asian patients. The journal was highly praised by experts for its detailed and professional content, especially the insightful viewpoints of experts.

Meanwhile, MicroPort® Endovascular invited Xiaoyong Huang, Deputy Director of Interventional Therapy Department of Beijing Anzhen Hospital of Capital Medical University, to give lectures to MicroPort® Endovascular marketing employees. Director Huang explained in detail the preoperative assessment of measurement in aortic endovascular treatment and the way to select the proper stent according to case characteristics. His lecture greatly benefited the MicroPort® Endovascular staff and will help them better serve the patients. MicroPort® Endovascular will continue to innovate and diversify our product pipeline, in accordance with our branding ideology "the Patient Always Comes First."